Prevalence of cardiac abnormalities and heart failure in unselected out-patients with type 2 diabetes mellitus and associated clinical factors: Real-world evidence from an Indian registry

被引:1
|
作者
Rajput, Rajesh [1 ]
Mohan, J. C. [2 ]
Sawhney, J. P. S. [3 ]
Dalal, Jamshed [4 ]
Mullasari, Ajit [5 ]
Vasnawala, Hardik [6 ]
Kumar, Amit [6 ]
Hs, Bharath [6 ]
Sarda, Shital [6 ]
机构
[1] PGIMS, Rohtak, India
[2] Jaipur Golden Hosp, Inst Heart & Vasc Dis, Sect 3, New Delhi, India
[3] Sir Ganga Ram Hosp, Delhi, India
[4] Kokilaben Dhirubhai Ambani Hosp, Mumbai, India
[5] MMM Hosp, Chennai, India
[6] AstraZeneca Pharm India Ltd, Med Affairs, Kochi, India
关键词
2-D echocardiography; Heart failure; Left ventricular dysfunction; Type 2 diabetes mellitus; LEFT-VENTRICULAR DYSFUNCTION; EUROPEAN-ASSOCIATION; AMERICAN-SOCIETY; CHAMBER QUANTIFICATION; ECHOCARDIOGRAPHY; RECOMMENDATIONS; GUIDELINES; UPDATE;
D O I
10.1016/j.ihj.2023.10.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Type 2 diabetes mellitus (T2DM) is known to be associated with development of left ventricular (LV) dysfunction and heart failure (HF). The study aimed to determine the prevalence of LV dysfunction and HF in unselected out-patients with T2DM with no previous cardiac history and to correlate LV dysfunction and HF with demographic and comorbid characteristics.Methods: This cross-sectional study conducted at 27 centers in India captured demographic and clinical data through electronic case record forms. B-type natriuretic peptide of >105 pg/mL was used to diagnose HF and two-dimensional echocardiography was used to assess LV dysfunction.Results: Of the 615 patients, 54.3 % (n = 334) were males; mean age was 57.4 +/- 10.48 years. More than one-third of the patients had T2DM duration of >10 years (n = 238; 38.7 %), with hypertension as the most prevalent comorbidity (n = 372, 78.6 %). Approximately 61.3 % of the patients had LV hypertrophy. The mean LV mass was 135.0 +/- 56.16 g (95 % CI 130.28, 139.70). The prevalence of any type of LV dysfunction, including systolic or diastolic dysfunction and HF was 55 % (95 % CI 51.0, 59.0) and 10 % (95 % CI 7.0, 12.0), respectively. A negligible but statistically significant correlation was observed between LV dysfunction and T2DM duration (p = 0.011), alongside HF and age (p < 0.0001).Conclusion: Real-world data from this registry from India demonstrates a substantial burden of LV dysfunction and HF in individuals with T2DM in India. It is imperative to formulate strategies for early identification of LV dysfunction in individuals with T2DM for prevention and consequent management of HF.
引用
收藏
页码:436 / 442
页数:7
相关论文
共 50 条
  • [1] PREVALENCE AND RISK FACTORS OF DIABETIC PERIPHERAL NEUROPATHY IN TYPE 2 DIABETES MELLITUS OUT-PATIENTS
    Gudala, K.
    Bansal, D.
    Muthyala, H.
    Bhansali, A.
    VALUE IN HEALTH, 2013, 16 (03) : A173 - A173
  • [2] REAL-world evidence of risk factors and comorbidities in YOUNG Indian adults with type 2 diabetes mellitus: A REAL YOUNG (diabetes) study
    Saboo, Banshi
    Agarwal, Sanjay
    Gupta, Sunil
    Makkar, Brij
    Panneerselvam, A.
    Sahoo, Abhay Kumar
    Ramchandani, G. D.
    Das, Sambit
    Erande, Suhas
    Kadam, Yogesh
    Abhyankar, Mahesh, V
    Revankar, Santosh
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (09) : 3444 - 3452
  • [3] Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT)
    Viswanathan, Vijay
    Singh, K. P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (08) : 415 - 422
  • [4] Reasons for discontinuing insulin and factors associated with insulin discontinuation in patients with type 2 diabetes mellitus: a real-world evidence study
    Jianmin Wu
    Fritha Morrison
    Zhenxiang Zhao
    Ginger Haynes
    Xuanyao He
    Ayad K. Ali
    Maria Shubina
    Shervin Malmasi
    Wendong Ge
    Xiaomei Peng
    Alexander Turchin
    Clinical Diabetes and Endocrinology, 7 (1):
  • [5] Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
    Gorgojo-Martinez, Juan J.
    Gargallo-Fernandez, Manuel A.
    Sanz-Pastor, Alba Galdon
    Anton-Bravo, Teresa
    Brito-Sanfiel, Miguel
    Wong-Cruz, Jaime
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 18
  • [6] Characteristics of type 2 diabetes patients with overt cardiovascular diseases in Malaysia: the real-world evidence from the National Diabetes Registry
    Kim Sui Wan
    Noran Naqiah Hairi
    Feisul Mustapha
    Muhammad Fadhli Mohd Yusoff
    Mastura Ismail
    Foong Ming Moy
    Noor Ani Ahmad
    BMC Research Notes, 18 (1)
  • [7] Heart failure among people with Type 2 diabetes mellitus: real-world data of 289 954 people from a diabetes database
    Stoyanova, D.
    Stratmann, B.
    Schwandt, A.
    Heise, N.
    Muehldorfer, S.
    Ziegelasch, H-J
    Zimmermann, A.
    Tschoepe, D.
    Holl, R. W.
    DIABETIC MEDICINE, 2020, 37 (08) : 1291 - 1298
  • [8] Real-World Demographics and Clinical Characteristics of Type 2 Diabetes Mellitus Patients in Ontario, Canada
    Houlden, Robyn L.
    Golden, Shane
    Shi, Wei Zhe
    Kukaswadia, Atif A.
    Sharma, Arushi
    Quansah, Kobina
    Liu, Aiden R.
    DIABETES, 2022, 71
  • [9] (#) Real-world usage of glucose lowering agents in heart failure patients with type 2 diabetes
    Martens, Pieter
    Janssens, Joyce
    Ramaekers, Jobbe
    Dupont, Matthias
    Mullens, Wilfried
    ACTA CARDIOLOGICA, 2019, 74 : 63 - 64
  • [10] Real-World Evidence Supports Higher Prevalence of Heart Failure Among Persons With Type 1 and Type 2 Diabetes Compared With the General Population
    Garrett, Valerie
    Gombar, Saurabh
    Huang, Jingtong
    Yeung, Andrea M. M.
    Klonoff, David C.
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023, 17 (03): : 864 - 865